Reuters: Health
Swiss drugmaker Novartis's Sandoz division has licensed from Polpharma Biologics a proposed biosimilar version of multiple sclerosis drug natalizumab, the companies said on Tuesday without giving financial details of the accord.
Novartis's Sandoz licenses proposed multiple sclerosis biosimilar
Novartis's Sandoz licenses proposed multiple sclerosis biosimilar
Reuters: Health
Swiss drugmaker Novartis's Sandoz division has licensed from Polpharma Biologics a proposed biosimilar version of multiple sclerosis drug natalizumab, the companies said on Tuesday without giving financial details of the accord.
Reuters: Health
Swiss drugmaker Novartis's Sandoz division has licensed from Polpharma Biologics a proposed biosimilar version of multiple sclerosis drug natalizumab, the companies said on Tuesday without giving financial details of the accord.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment